Drug Trial Radar · NCT07252440
A Study to Evaluate the Efficacy and Safety of TTYP01 Tablets in Early Symptomatic Alzheimer's Disease
Last checked: Nov 19, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
Dec 19, 2025
Primary completion
Oct 23, 2028
Study completion Nov 23, 2028
Sponsor
- Lead sponsor
- Shanghai Auzone Biological Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 26, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 55 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, placebo-controlled parallel Phase II core period study to evaluate the efficacy and safety of TTYP01 Tablets in early symptomatic AD (Mild cognitive impairment \[MCI\] due to AD, or mild AD dementia). A total of 180 participants will be randomized into 3 parallel groups: 2 TTYP01 dose groups and 1 placebo group.
Conditions
- AD
- Early Alzheimer's Disease
Interventions
TTYP01 tables 60mgDrug
2 TTYP01 30 mg tablets + 1 placebo tablet BID
TTYP01 tables 90mgDrug
(3 TTYP01 30 mg tablets
TTYP01 tables 0mgDrug
3 placebo tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) score at Week 78.Time frame: Baseline to Week 78
- Number of participants with Adverse events, serious adverse events, adverse events of special interestTime frame: Baseline to Week 78
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Daping Hospital.
Chongqing, Chongqing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.